Key Highlights

  • 0.13 is the consensus loss per share expected from Daré Bioscience, Inc. (NASDAQ:DARE) for the quarter ended September 30, 2026, compared with a reported loss of 0.20 per share in the second quarter of 2026.
  • 12.6 million is the USD cash balance held at June 30, 2026, down 48.9% from USD 24.7 million at December 31, 2025, a decline of USD 12.1 million, calculated from the reported balance sheet.
  • 2.98 million is the USD net loss reported for the second quarter of 2026, narrower than the USD 4.02 million loss a year earlier as Research and Development expense fell to USD 0.24 million.
  • 4:30 p.m. ET is the start time of the November 16, 2026 conference call, where management is expected to review the quarter, sildenafil cream dispensing, the Ovaprene Phase 3 study and the DARE-HPV program.

What Investors Expect From Daré Bioscience (NASDAQ:DARE) on November 16, 2026

Daré Bioscience, Inc. will report results for the quarter ended September 30, 2026 on Monday, November 16, 2026, and has scheduled a conference call for 4:30 p.m. ET to review the quarter and provide a company update. The consensus estimate calls for a loss of 0.13 per share. In the second quarter of 2026 the company reported a loss of 0.20 per share on 14,889,832 weighted average shares, against a loss of 0.45 per share on 8,871,155 shares a year earlier. A result near the estimate would represent an improvement of 0.07 per share from the second quarter, calculated. Published market data show the shares closed at USD 0.68 on November 9, 2026.

The Rationale: Last Reported Quarter and Management Outlook for Daré Bioscience (NASDAQ:DARE)

For the quarter ended June 30, 2026, total Revenue was USD 187,546, compared with negative USD 21,172 a year earlier, with cost of revenues of USD 319,889. Selling, general and administrative expense was USD 2,593,671, while research and development expense, net of grant offsets of about USD 4.7 million, fell to USD 241,966 from USD 1,428,762. The loss from operations was USD 2,967,980 and net loss was USD 2,982,773 versus USD 4,016,483, a reduction of USD 1,033,710, calculated. Management has issued no numeric guidance. It expects prescription dispensing and initial product revenue from sildenafil cream in the third quarter of 2026, and DARE to RECLAIM dispensing is targeted for 2027. Interim Phase 3 results for Ovaprene were positive.

Valuation, Liquidity and Risks for Daré Bioscience (NASDAQ:DARE)

Cash and equivalents were USD 12,617,594 at June 30, 2026, against USD 24,711,356 at December 31, 2025. Total Assets were USD 22,370,109, Working Capital was a Deficit of USD 236,457 including a deferred grant funding Liability of roughly USD 15.0 million, and stockholders' Equity was a deficit of USD 560,100. The company cites the ability to raise capital when needed, and the possible suspension and delisting of its common stock from the Nasdaq Capital Market, among its risk factors.

Where Things Stand

Daré Bioscience, Inc. (NASDAQ:DARE) reports on November 16, 2026 with the consensus estimate at a loss of 0.13 per share, an improvement from the 0.20 loss of the second quarter. Cash stood at USD 12.6 million at June 30, 2026, after falling by USD 12.1 million in six months, calculated, so liquidity commentary will matter. The first quarter of product revenue from sildenafil cream, guided for the third quarter of 2026, is the main operating item, alongside Ovaprene Phase 3 progress and 2027 targets for DARE-HPV topline data and DARE to RECLAIM dispensing. This article is informational and is not Investment advice.